|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues显示文摘AIM: To study estrogen receptor (ER) and estrogen receptor messenger RNA (ERmRNA) expression in gastric carcinoma tissues and to investigate their association with the pathologic types of gastric carcinoma.METHODS: The expression of ER and ERmRNA in gastric carcinoma tissues (15 males and 15 females, 42-70 years old) was detected by immunohistochemistry and in situ hybridization, respectively.RESULTS: The positive rate of ER (immunohistochemistry)was 33.3% in males and 46.7% in females. In Borrmann Ⅳ gastric carcinoma ER positive rate was greater than that in other pathologic types, and in poorly differentiated adenocarcinoma and signet ring cell carcinoma the positive rates were greater than those in other histological types of both males and females (P<0.05). The ER was more highly expressed in diffused gastric carcinoma than in non-diffused gastric carcinoma (P<0.05). The ER positive rate was also related to regional lymph nodes metastases (P<0.05), and was significantly higher in females above 55 years old, and higher in males under 55 years old (P<0.05). The ERmRNA (in situ hybridization) positive rate was 73.3% in males and 86.7% in females. The ERmRNA positive rates were almost the same in Borrmann Ⅰ, Ⅱ, Ⅲ and Ⅳ gastric carcinoma (P>0.05). ERmRNA was expressed in all tubular adenocarcinoma, poorly differentiated adenocarcinoma and signet ring cell carcinoma (P<0.05). The ERmRNA positive rate was related to both regional lymph nodes metastases and gastric carcinoma growth patterns, and was higher in both sexes above 55 years old but without statistical significance (P>0.05). The positive rate of ERmRNA expression by in situ hybridization was higher than that of ER expression by immunohistochemistry (P<0.05).CONCLUSION: ERmRNA expression is related to the pathological behaviors of gastric carcinoma, which might help to predict the prognosis and predict the effectiveness of endocrine therapy for gastric carcinoma. | Xin-HanZhao Shan-ZhiGu Shan-XiLiu Bo-RongPan | 2003 | World Journal of Gastroenterology2003，9，4： | 36 |
| 2 | Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells显示文摘AIM: To study the effect of hydroxyapatite (HAP) nanoparticleson human hepatoma cell line BEL-7402 in vitro.METHODS: The human hepatoma cell line BEL-7402 wascultured and treated with HAP nanoparticles at variousconcentrations. Growth suppression was detected with MTTcolorimetric assay, cell apoptotic alterations were evaluatedby cytochemical staining (Hoechst 33258), transmissionelectron microscopy (TEM), and flow cytometry (FCM).RESULTS: HAP nanoparticles inhibited the growth ofhepatoma cells in a dose-dependent manner, with IC50 valuesof 29.30 mg/L. Treated with 50-200 mg/L HAP nanoparticlesfor 48 h, BEL-7402 cells apoptosis with nuclear chromatincondensation and fragmentation as well as cell shrinkageand the formation of apoptotic bodies were observed undercytochemical staining and transmission electron microscopy.FCM analysis showed hypodiploid peaks on histogram, theapoptotic rates at the concentrations of 50, 75, 100, 150and 200 mg/L of HAP nanoparticles were 20.35±2.23%,25.35±1.92%, 29.34±4.61%, 44.92±3.78 % and53.64±3.49%, respectively, which were all significantlyhigher than that of control group 2.23±0.14%. There wasa significant correlation between HAP nanoparticleconcentration and apoptotic rate (r=0.994, P<0.01).CONCLUSION: HAP nanoparticles not only inhibitproliferation but also induce apoptosis of human hepatoma cell line BEL-7402 in vitro. | Zhi-Su Liu Sheng-Li Tang Zhong-Li Ai Department of General Surgery,Zhongnan Hospital of Wuhan University,Wuhan 430071,Hubei Province,China | 2003 | World Journal of Gastroenterology2003，9，9： | 33 |
| 3 | Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer显示文摘AIM: Preoperative intra-arterial infusion chemotherapy could increase the radical resection rate of advanced gastric cancer, but its effect on the long-term survival has not been assessed. This study was designed to evaluate the clinical significance of preoperative intra-arterial infusion chemotherapy for advanced gastric cancer. METHODS: Clinicopathological data of 91 patients who underwent curative resection for advanced gastric cancer were collected. Among them, 37 patients undertaken preoperative intra-arterial infusion chemotherapy were used as the interventional chemotherapy group, and the remaining 54 patients as the control group. Eleven factors including clinicopathological variables, treatment procedures and molecular biological makers that might contribute to the long-term survival rate were analyzed using Cox multivariate regression analysis.RESULTS: The 5-year survival rate was 52.5% and 39.8%,respectively, for the interventional group and the control group (P<0.05). Cox multivariate regression analysis revealed that the TNM stage (P<0.001), preoperative intraarterial infusion chemotherapy (P=0.029) and growth pattern (P=0.042) were the independent factors for the long-term survival of patients with advanced gastric cancer. CONCLUSION: Preoperative intra-arterial infusion chemotherapy plays an important role in improving the prognosis of advanced gastric cancer. | Cheng-WuZhang Shou-ChunZou DunShi Da-JianZhao Cheng-WuZhang | 2004 | World Journal of Gastroenterology2004，10，20： | 30 |
| 4 | 努力提高胃癌的术后5年生存率显示文摘目前我国胃癌的发病率和病死率仍处于所有恶性肿瘤的前位,据卫生部2005年统计.每年新发胃癌病人约40万人,死亡约30万人。我国近年多数临床报道显示,胃癌的整体疗效已有所改善.总体5年生存率达到30%左右,根治性手术后生存率提高至50%。西方国家的较新资料显示,可切除胃癌的5年生存率仍徘徊在10%~30%;相比较,日本的可切除胃癌5年生存率则为60%左右.优于我国及西方国家的疗效。 | 秦新裕 刘凤林 | 2008 | 外科理论与实践2008，13，1： | 20 |
| 5 | 进展期胃癌介入治疗疗效分析显示文摘目的研究进展期胃癌的介入治疗及疗效。方法对212例进展期胃癌进行介入治疗。对贲门癌经胃左动脉和左膈下动脉或脾动脉进行化疗灌注和胃左动脉栓塞;对胃体小弯侧癌经胃左、右动脉或肝总动脉,对胃大弯侧癌经胃十二指肠动脉、胃网膜右动脉或脾动脉化疗灌注;对胃窦癌经胃十二指肠动脉或对胃网膜右动脉中段栓塞后进行化疗药物灌注。对胃癌复发和残胃癌经腹腔干和肠系膜上动脉化疗灌注。结果对未手术的193例胃癌的疗效为贲门癌CR+PR53.1%,胃体癌CR+PR44.4%,胃窦癌CR+PR10.0%,胃癌复发和残胃癌CR+PR0。贲门癌与胃体癌有效率相比(P>0.25),两者差异无统计学意义。贲门癌与胃窦癌相比及胃体癌与胃窦癌相比,差异有统计学意义(P值均<0.05)。介入治疗后手术切除者术后1、2年生存率分别为81%、56%。结论胃癌在胃组织的发病部位不同,其疗效也不同,贲门癌和胃体癌的疗效较好,胃窦癌及胃癌复发和残胃癌疗效较差。 | 朱明德 张子敬 季洪胜 郝刚 葛成林 魏孔朋 袁玉厚 赵秀萍 | 2008 | 介入放射学杂志2008，17，2： | 19 |
| 6 | 新辅助化疗对胃癌5年生存率影响的Meta分析显示文摘目的应用Meta分析的方法探讨术前新辅助化疗对胃癌5年生存率的影响。方法通过Pubmed、Cochrane图书馆、EMBASE、Ovid检索系统、Google搜索引擎及手工检索有关胃癌新辅助化疗的临床对照研究。按纳入排除标准进行筛选,并对入选研究的文献进行质量评价,提取资料进行Meta分析。结果 2000~2007年共8项随机对照试验1 510例胃癌患者纳入分析,其中新辅助化疗后手术治疗组718例,直接手术组792例。Meta分析结果显示新辅助化疗后手术与直接手术相比,死亡风险优势比(OR)值为0.67,95%可信区间为0.53~0.83,P=0.000 3,差异有统计学意义。结论与直接手术相比,手术前行新辅助化疗与提高患者5年生存率有一定相关性。 | 田洪鹏 王继见 | 2012 | 重庆医学2012，41，2： | 18 |
| 7 | 术前区域性辅助化疗对改善胃癌手术疗效的临床意义显示文摘 | 朱正纲 | 2005 | 中国实用外科杂志2005，25，7： | 16 |
| 8 | Apoptosis-inducing effect of recombinant Caspase-3 expressed by constructed eukaryotic vector on gastric cancer cell line SGC7901显示文摘AIM: To investigate the apoptosis-inducing effect of Caspases-3 expressed by constructed eukaryotic vector on gastric cancer cell line SGC7901.METHODS: PCR was employed to amplify the sequences of both small and large subunits of Caspases-3. Its products were separately cloned into the Sma I site of pBluescript KS+ to generate both plasmids pBS/SS and pBS/LS. The small subunit fragment was excised from plasmid pBS/SS with BarrH- I and then inserted into the BarnH I site of plasmid pBS/LS preceding that of the large subunit to yield plasmid pBS/Rev-Caspase-3. Rev-Caspase-3 cDNA was excised with Kpn Ⅰ+Xba I and then subcloned into plasmid pcDNA3.1(+) to construct Rev-Caspase-3 eukaryotic expression vector pcDNA/Rev-Caspase-3, which was used to transiently transfect SGC7901 cell line. Cell count, MTT assay and electron microscopy were used to confirm the antiproliferation and apoptosis-inducing effect of Rev-Caspase-3 expression on gastric cancer cells.RESULTS: Plasmid pBS/Rev-Caspase-3 and eukaryotic expression vector pcDNA/Rev-Caspase-3 were successfully constructed. SGC7901 cells were transiently transfected by either pcDNA/Rev-Caspase-3 or pcDNA3.1 (+) for 24, 48,72, and 96 h respectively. Cell growth was measured by cell count and MTT assay. In cell count assay, the cell numbers were 1.S×106, 1.55×106, 2.0×106, and 3.1×106 in the experimental group and 2.5×106, 3.1×106, 4.0×106, and 5.7×106 in the control group at 24, 48, 72 and 96 h respectively.The growth of SGC7901 cells was suppressed by RevCaspase-3 in a time-dependent manner (P<0.05). The results of MTT assay were similar to that of cell count (P<0.05).The characteristics of apoptosis such as chromatin condensation, crescent formation and margination were seen and more obvious with time in the given-experimental period in the experimental group, but not easily observed in the control group.CONCLUSION: The expression of Rev-Caspase-3 by the constructed eukaryotic vector can significantly induce apoptosis of gastric cancer cell line SGC7901, which may exhibit a potential way in gastric cancer gene therapy. | Yuan-GenFu Yao-JunQu Kai-ChunWu Hui-HongZhai Zhi-GuoLiu Dai-MingFan | 2003 | World Journal of Gastroenterology2003，9，9： | 16 |
| 9 | Apoptosis of hepatoma cells SMMC-7721 induced by Ginkgo biloba seed polysaccharide显示文摘AIM: To study the apoptosis of hepatoma cells SMMC-7721induced by polysaccharide isolated from Ginkgo biloba seed.METHODS: Ginkgo biloba seed polysaccharide (GBSP) wasisolated by ethanol fractionation of Ginkgo biloba seed andpurified by Sephadex G-200 chromatography. The purity ofGBSP was verified by reaction with iodine-potassium iodideand ninhydrin and confirmed by UV spectrophotometer,cellulose acetate membrane electrophoresis and Sepharose4B gel filtration chromatography. The Scanning ElectronMicroscope (SEM) and Flow Cytometrv (FCM) were used toexamine the SMMC-7721 cells with and without GBSPtreatment at 500 mg/ml for 36 h.RESULTS: GBSP product obtained was of high purity withthe average molecular weight of 1.86 × 105. Quantitativeanalysis of SMMC-7721 cells in vitro with FCM showed thatthe percentages of G2-M cells without and with GBSPtreatment were 17.01±1.28 % and 11.77±1.50% (P<0.05),the debds ratio of the cells were 0.46±0.12 % and 0.06±0 .06 %(P<0.01), and the apoptosis ratio of cells was 3.84±0 .55 %and 9.13±1.48 %(P<0.01) respectively. Following GBSPtreatment, microvilli of SMMC-7721 cells appeared thinnerand the number of spherical cells increased markedly. Mostsignificantly, the apoptosis bodies were formed on andaround the spherical cells treated with GBSP.CONCLUSION: GBSP could potentially induce the apoptosisof SMMC-7721 cells. | Gui-Wen Yang Li-Guo An Department of Biology,Shandong Normal University,Jinan 250014,Shandong Province,China Qun Chen Department of Biology & Chemistry,Huainan Teachers College,Huainan 232001,Anhui Province,China | 2002 | World Journal of Gastroenterology2002，8，5： | 15 |
| 10 | 进展期胃癌术前区域动脉灌注化疗进展显示文摘进展期胃癌的单纯手术治疗效果不理想,术后仍有较高的局部复发率和远处转移率。近年来,通过新辅助化疗减少肿瘤负荷,降低肿瘤分期,增加手术切除率,提高远期疗效,已逐步受到人们的重视。其中术前区域动脉灌注化疗直接作用于肿瘤的血管内皮细胞,局部药物浓度高。全身毒副作用小,为进展期胃癌提供了一种有效的治疗方法。本文就进展期胃癌术前区域动脉灌注化疗的适应证、并发症、疗效评价、手术时机、化疗方案及病理改变等方面进行一综述。 | 李占武 王利 | 2013 | 中华胃肠外科杂志2013，16，2： | 15 |
| 11 | 进展期消化道肿瘤术前介入治疗的评价显示文摘 | 秦新裕 许剑民 刘凤林 钟芸诗 | 2005 | 中国实用外科杂志2005，25，5： | 13 |
| 12 | 奥沙利铂综合治疗胃癌的疗效及机制显示文摘目的:评价奥沙利铂(Oxaliplatin,L-OHP)对人胃癌的疗效,探讨其治疗胃癌的作用机制。方法:Ⅳ期胃癌患者22例接受包含L-OHP的联合化疗方案(L-OHP 85 mg/m^2,静脉点滴,1h,第1d;四氢叶酸钙200 mg/m^2,静脉点滴,1h,第1-5 d;5-FU 300mg/m^2,静脉注射,第1-2d,5-FU,持续静脉点滴,48h;2wk1疗程)4-6(平均4.6)个疗程.观察有效率,无进展生存时间(progression-free survival,PFS),总体生存时间及毒副作用。体外培养人中分化胃癌细胞株SGC-7901,应用MTT法检测L-OHP对细胞生长的抑制作用,并计算50%抑制浓度(IC_(50));将不同浓度梯度的L-OHP与细胞株作用后,应用流式细胞仪(ANEXIN-V标记)及TUNEL检测细胞凋亡情况。应用RT-PCR检测caspase-3m-RNA的表达。结果:有效(完全有效及部分有效)9例(40.9%)。平均PFS4.2mo,总体生存时间7.2mo。蓄积性神经毒性(全部为Ⅰ-Ⅱ级),呕吐及腹泻(1例Ⅲ级腹泻),骨髓抑制发生率分别为93.5%,20%,32.9%.浓度为1mmol/L的L—OHP与细胞株作用30min,流式细胞仪即可检测出细胞凋亡水平升高,但无统计学差异(P>0.05),1mmol/L作用2d,流式细胞仪及TUNEL均可检测到细胞凋亡水平显著性升高(P<0.05)。L-OHP作用后的细胞caspase-3 m-RNA表达升高,并与药物诱导的凋亡相关。结论:L-OHP治疗进展期胃癌安全有效.L-OHP在体外可明显抑制胃癌细胞株SGC-7901的生长,诱导细胞caspase-3m-RNA表达及凋亡。 | 林万隆 李定国 陈强 陆汉民 马小明 孙培龙 | 2003 | 世界华人消化杂志2003，11，10： | 12 |
| 13 | 以奥沙利铂为主介入治疗结直肠癌肝转移的效果显示文摘目的:探讨以奥沙利铂为主的肝动脉灌注化疗对结直肠癌多发肝转移患者的治疗效果.方法:经肝动脉灌注化疗的结直肠癌多发肝转移患者26例为治疗组,共行肝动脉灌注及栓塞治疗58次,药物包括奥沙利铂130mg/m2,亚叶酸钙200mg/m2,5-FU750mg/m2.同期进行改良FOLFOX4方案全身化疗结直肠癌肝转移患者20例为对照组,观察治疗前后患者近期疗效、全身情况变化情况以及化疗后毒性反应.结果:治疗组近期疗效为57.7%,好于对照组的40.0%(P<0.05);治疗组Karmofsky评分提高率高于治疗前(P<0.05).对照组低于治疗前(P<0.05);治疗组毒副作用如恶心呕吐较对照组轻(P<0.05).结论:与FOLFOX4方案相比,以奥沙利铂为主的肝动脉灌注化疗能提高结直肠癌多发肝转移患者的近期疗效. | 马建仓 赵军 戴社教 张大华 苏清华 谢忠海 纪宗正 | 2007 | 第四军医大学学报2007，28，1： | 11 |
| 14 | 胃癌化疗方式研究进展显示文摘胃癌是消化道最常见的高度恶性的肿瘤,其预后差,治疗难度大,死亡率高。过去的20年间,为了增加胃癌患者的手术治疗机会,提高生存率,改善预后,国内外进行了大量辅助化疗方面的研究,积极寻找新的放化疗方案和辅助化疗方式。虽然最近开展了许多化疗方案,但未取得很显著的疗效,所以目前对进展期胃癌的治疗,没有一个标准的方案。 | 沈波 朱金水 | 2005 | 国外医学(消化系疾病分册)2005，25，3： | 10 |
| 15 | 胃癌切除术后化疗治疗效果的系统评价显示文摘目的 评价胃癌切除术后的不同药物、剂量、经静脉化疗方案的疗效和安全性。方法 计算机检索Medline和Embase(1980 - 2 0 0 1.4 ) ,检索词“chemotherapy ,stomachneoplasms ,surgery” ,并限制文章语言种类为English ;同时计算机检索中国生物医学文摘数据库 (1990 - 2 0 0 1.1) ,检索词“化疗 ,胃癌 ,手术”。对资料进行初筛 ,选取试验包括上述治疗组和对照组的文献 ,然后筛除明显不是随机临床试验的研究 ,对剩余的文献开始查找全文 ,进一步判断是否为RCT。纳入标准为 :(1)随机临床试验 (randomisedclinicaltrial,RCT)无论是否为单盲、双盲或非盲法 ;(2 )试验包含平行的对照组 ,即仅行胃癌根治性 /姑息性切除手术 (原发包块切除 ) ,术后不接受任何途径的化疗或仅接受安慰剂治疗 ;(3)治疗组为胃癌根治性 /姑息性切除术后接受不同药物、剂量的静脉化疗者 ;(4 )术前未接受化疗、放疗或其它肿瘤治疗。排除标准 :任何时间接受了放疗、免疫治疗、生物治疗者。应用国际Cochrane协作网的系统评价方法对全世界关于胃癌切除术后接受不同药物、剂量、经静脉化疗组与单纯手术组疗效的随机和半随机试验进行了系统评价。结果 共收集到 2 7篇关于胃癌切除术后接受不同药物、剂量、经静脉化疗组与单纯手术组疗效的随? | 胡建昆 陈志新 张波 田静 陈佳平 周总光 王莉 王朝华 陈红艳 | 2003 | 中国循证医学杂志2003，3，1： | 10 |
| 16 | 胃癌供血及其动脉介入化疗的研究进展显示文摘胃癌是我国最常见的恶性肿瘤之一,其预后差,只有40%的就诊患者能进行手术治疗,即使进行完全切除的患者,胃癌的复发率非常高.由于胃癌血供复杂多变的特点,及血管生长因子影响肿瘤生长学说的兴起和血管生长抑制剂的不断发现,其抑制实体肿瘤生长及转移的实验研究和临床上的应用,使进展期胃癌的治疗趋于多元化,并且近年兴起的血管介入化疗中,不断新的辅助化疗方案的研究,以提高患者行手术治疗的比率及改善生活质量.其中自体干细胞支持下超选择局部动脉化疗在肿瘤治疗上的应用,其减少药物的副反应,提高有效率,延长生存期的优势,为晚期胃癌的治疗提供了新的方向. | 沈波 朱金水 | 2003 | 世界华人消化杂志2003，11，9： | 9 |
| 17 | 胃左动脉联合食管固有动脉化疗栓塞治疗中晚期贲门癌的疗效显示文摘目的观察分析胃左动脉联合食管固有动脉化疗栓塞治疗中晚期贲门癌临床价值。方法回顾性分析自2015年3月至2017年12月收治的52例中晚期贲门癌患者,其中25例采用贲门癌胃左动脉灌注化疗药物并栓塞(称常规组),联合组27例在常规组基础上追加食管固有动脉灌注化疗栓塞。术后定期复查上消化道造影、上腹部CT等。采用Kaplan-Meier法计算生存时间,Log-rank检验比较2组患者的生存曲线。结果患者随访3~27个月,术后常规组总缓解率达48%,联合组总缓解率达77.8%,吞咽困难改善程度联合组优于常规组,差异有统计学意义(P<0.05)。常规组中位生存期为12个月,6、12、18、24个月生存率分别为76%(19/25)、48%(12/25)、16%(4/25)、0,联合组中位生存期为17个月,6、12、18、24个月生存率分别为92.6%(25/27)、77.8%(21/27)、37%(10/27)、7.4%(2/27),生存曲线的差异有统计学意义(Log-rank检验,χ~2=5.973,P<0.05)。结论胃左动脉联合食管固有动脉灌注化疗栓塞治疗中晚期贲门癌较单纯胃左动脉灌注化疗栓塞能更有效地控制肿瘤病灶发展、改善患者症状,延长生存期,在临床治疗中有一定价值。 | 李方正 任建庄 韩新巍 陈鹏飞 许琳惠 万里 王家兴 | 2019 | 介入放射学杂志2019，28，5： | 8 |
| 18 | 区域动脉灌注化疗在进展期胃癌短程新辅助化疗中的应用显示文摘目的 探讨短程新辅助化疗应用于进展期胃癌的可行性,并比较不同化疗方式短程新辅助化疗的临床疗效.方法 回顾性分析2008年1月至201 1年12月间在南京中医药大学附属医院接受短程(1个周期)EOF方案(表柔比星、奥沙利铂、氟尿嘧啶加亚叶酸钙)新辅助化疗的310例进展期胃癌患者的临床资料.比较全身静脉化疗方案与区域动脉灌注化疗方案的临床疗效.结果 310例患者均完成了1个周期的短程EOF方案新辅助化疗,无一例因化疗毒副反应而终止.术后病理缓解率为33.9%(105/310),其中5例(1.6%)获病理完全缓解.接受区域动脉灌注化疗者的病理缓解率为42.4%(72/170),明显高于全身静脉化疗者的23.6% (33/140) (P=0.001).Logistic多因素回归分析证实,化疗方式是影响进展期胃癌短程新辅助化疗后病理缓解率的独立危险因素(HR=1.827; 95% CI:1.006~3.316; P=0.048).结论 进展期胃癌短程新辅助化疗病理缓解率总体较低;区域动脉灌注化疗能提高进展期胃癌短程新辅助化疗的术后病理缓解率。 | 吴震峰 朱文强 曹勤洪 陈志伟 吴晓宇 陈彻 许哲 李为苏 姚学权 | 2014 | 中华胃肠外科杂志2014，17，11： | 7 |
| 19 | 胃癌介入化疗与全身化疗的疗效比较显示文摘目的:评价胃癌介入化疗与全身化疗的疗效。方法:对60例经病理证实的胃癌患者进行回顾性分析,其中术前经介入插管化疗32例,全身性化疗28例,所用药物为氟尿嘧啶脱氧核苷(FuDR)、阿霉素等。结果:介入插管化疗组总有效率81.25%。全身性化疗组总有效率50.00%。结论:中晚期胃癌介入化疗疗效优于全身化疗。 | 潘彦康 | 2009 | 吉林医学2009，30，15： | 6 |
| 20 | 槲皮素联合顺铂对胃癌SGC-7901细胞增生和凋亡的影响显示文摘目的:探讨槲皮素(quercetin,QU)联合顺铂(DDP)对胃癌SGC-7901细胞增生、凋亡及凋亡相关基因Bcl-XL mRNA表达的影响. 方法:用槲皮素和顺铂处理胃癌SGC-7901细胞后,应用光镜、电镜、MTT法、流式细胞仪和RT-PCR 技术研究胃癌细胞的形态学变化、生长抑制、诱导凋亡和对凋亡相关基因Bcl-XL mRNA表达的影响. 结果:药物作用于细胞24 h后,可看到较为典型的细胞凋亡形态学变化.DDP和QU均可以抑制胃癌SGC-7901 细胞增生或诱导其凋亡,且有时间和剂量依赖效应,联合应用具有协同效应.联合组的诱导凋亡率及增生抑制效应显著高于单用DDP组(P<0.01),干预48 h后,Bcl- XLmRNA的表达下调,QU可以加强下调作用. 结论:人胃癌SGC-7901细胞体外实验中,QU和顺铂可以抑制其增生并诱导凋亡,二者联合应用有一定的协同效应,且呈剂量依赖关系. | 王海忠 王沁 | 2005 | 世界华人消化杂志2005，13，3： | 6 |
您所在的机构暂未开通此部分的功能，请联系管理员